IVF – R3 Medical

Fertility Treatments

Medical Tourism

IVF (In Vitro Fertilization)

R3 Medical Tourism | Elite Fertility Care in Tijuana, Mexico

What Is IVF (In Vitro Fertilization)?

In vitro fertilization (IVF) is the most widely used and comprehensively studied assisted reproductive technology (ART) in the world. The procedure involves stimulating the ovaries to produce multiple mature eggs, retrieving those eggs from the ovaries through a minimally invasive procedure, fertilizing them with sperm in a specialized embryology laboratory, culturing the resulting embryos for 3 to 5 days, and then transferring one or more embryos into the uterus where implantation and pregnancy can occur. The phrase ‘in vitro’ — Latin for ‘in glass’ — reflects the fact that fertilization occurs outside the body in a controlled laboratory environment rather than naturally within the fallopian tube.

IVF was pioneered by British physiologist Robert Edwards and gynecologist Patrick Steptoe, whose work led to the birth of Louise Brown — the world’s first IVF baby — on July 25, 1978. Edwards was awarded the Nobel Prize in Physiology or Medicine in 2010 for this work. Since then, the technology has undergone continuous refinement: improved ovarian stimulation protocols, laboratory culture media and conditions optimized for embryo development, blastocyst-stage (day 5) culture, pre-implantation genetic testing (PGT), vitrification (ultra-rapid freezing) of embryos, and individualized patient protocols have collectively transformed IVF from an experimental procedure into a reliable, widely accessible reproductive treatment with well-established success benchmarks.

IVF may be performed with the patient’s own eggs and partner’s sperm (conventional IVF), with donor eggs or sperm, with previously frozen embryos (frozen embryo transfer, FET), or using a gestational carrier (surrogacy). The flexibility of IVF to accommodate diverse family-building scenarios has made it the cornerstone of modern reproductive medicine.

Who Is IVF For?

IVF is indicated for a wide range of patients experiencing infertility — defined as the inability to conceive after 12 months of regular unprotected intercourse (or 6 months for women over 35). The most common indications include tubal factor infertility (blocked, damaged, or absent fallopian tubes that prevent natural fertilization), severe male factor infertility (significantly reduced sperm count, motility, or morphology), ovulatory disorders that have not responded to ovulation induction medications, endometriosis affecting fertility, unexplained infertility after failed intrauterine insemination attempts, diminished ovarian reserve requiring aggressive stimulation to retrieve usable eggs, and recurrent pregnancy loss where pre-implantation genetic testing of embryos may reduce miscarriage risk.

IVF is also the treatment of choice for same-sex female couples (using donor sperm), single women seeking pregnancy, same-sex male couples requiring both egg donation and gestational surrogacy, and individuals who wish to preserve fertility before cancer treatment or for elective reasons. Patients with genetic disorders that carry a high risk of transmission to offspring may combine IVF with pre-implantation genetic testing for monogenic disorders (PGT-M) to select unaffected embryos for transfer.

Age is one of the most critical factors in IVF success: live birth rates per retrieval cycle decline progressively from the mid-30s and fall substantially after age 40 using the patient’s own eggs. Women over 40 or those with severely diminished ovarian reserve are often counseled to consider donor egg IVF, which restores live birth rates to those of the donor’s age. A thorough fertility evaluation — including antral follicle count (AFC), anti-Mullerian hormone (AMH) measurement, day 3 FSH and estradiol, hysterosalpingography (HSG) for uterine and tubal assessment, and semen analysis — guides individualized treatment planning.

IVF Treatment Videos

It is a long established fact that a reader will be distracted by the readable content of a page when looking at its layout. The point of using Lorem Ipsum is that it has a more-or-less normal distribution of letters, as opposed to using..

Frequently Asked Questions

Why Get IVF in Tijuana with R3 Medical Tourism?

For couples and individuals who have struggled with infertility, IVF often represents the most direct path to the family they have been working toward — offering success rates that far exceed any other fertility treatment for appropriate candidates. The emotional weight of infertility is profound, and IVF provides both a scientifically rigorous process and, for many patients, the fulfillment of a deeply held life goal.

Tijuana is home to internationally accredited fertility clinics staffed by reproductive endocrinologists who trained at leading programs in Mexico, the United States, and Europe. R3 Medical Tourism partners exclusively with clinics that maintain certified embryology laboratories, advanced culture systems (time-lapse embryo incubators such as EmbryoScope), vitrification capabilities, and the full range of ART services including PGT. These clinics operate under the regulatory oversight of Mexico’s health authorities and meet the laboratory and clinical standards established by the Red Latinoamericana de Reproduccion Asistida (REDLARA) and international reproductive medicine societies.

The financial advantage of IVF in Tijuana is one of the most compelling in all of medical tourism. A single IVF cycle in the United States averages $15,000 to $25,000 when medications are included, and most insurance plans provide limited or no coverage. In Tijuana, a complete IVF cycle with monitoring, retrieval, fertilization, and fresh embryo transfer typically costs $4,000 to $7,000 — savings of 65 to 75 percent. For patients who require multiple cycles, the cumulative savings are transformative, enabling access to the number of attempts that statistically maximize the probability of success.

How Is IVF Performed?

A standard IVF cycle proceeds through five distinct phases. Ovarian stimulation begins on day 2 or 3 of the menstrual cycle with daily self-administered injectable gonadotropins (follicle-stimulating hormone, FSH, with or without luteinizing hormone, LH) that stimulate the ovaries to develop multiple follicles simultaneously. Stimulation typically lasts 8 to 14 days and is monitored with serial transvaginal ultrasounds and estradiol blood tests every 2 to 3 days to assess follicle growth and adjust medication doses. A GnRH antagonist (cetrorelix, ganirelix) or long GnRH agonist protocol prevents premature ovulation during stimulation.

When the leading follicles reach approximately 18–20 mm in diameter, a trigger injection — typically human chorionic gonadotropin (hCG) or a GnRH agonist trigger — is administered to induce final egg maturation. Exactly 34 to 36 hours later, transvaginal oocyte retrieval is performed under ultrasound guidance while the patient is under intravenous sedation. A thin needle is passed through the vaginal wall into each follicle and the follicular fluid containing the eggs is aspirated. The embryologist immediately identifies and grades the retrieved eggs under a microscope.

Fertilization is performed the same day: in conventional IVF, approximately 100,000 to 500,000 motile sperm are placed together with each mature egg in a culture dish; in ICSI, a single sperm is injected directly into each egg. Fertilization is confirmed the following morning by the presence of two pronuclei. Embryos are cultured in a specialized incubator for 3 to 5 days, with the majority of clinics now preferring blastocyst-stage culture (day 5), which allows better selection of the most viable embryos. One or two embryos are selected for transfer into the uterus using a thin catheter under abdominal ultrasound guidance. A pregnancy test (serum beta-hCG) is performed approximately 10 to 14 days after transfer.

Outcomes and What the Data Shows

IVF success rates are reported by the CDC and the Society for Assisted Reproductive Technology (SART) in the United States and by REDLARA for Latin American clinics. The most clinically meaningful metric is the live birth rate per embryo transfer, which varies significantly by patient age and egg source. According to 2021 SART data, the live birth rate per intended egg retrieval using the patient’s own eggs is approximately 46% for women under 35, 37% for ages 35–37, 29% for ages 38–40, and 12% for ages 41–42. With donor eggs, live birth rates exceed 40–50% across all recipient age groups, reflecting the donor’s younger egg quality.

The advent of blastocyst culture, pre-implantation genetic testing for aneuploidy (PGT-A), and vitrified frozen embryo transfer (FET) has meaningfully improved outcomes over the past decade. A 2019 meta-analysis in Fertility and Sterility found that PGT-A with single euploid frozen embryo transfer achieves live birth rates of 55–65% per transfer in women under 38, with miscarriage rates below 10% — substantially better than untested embryo transfers. Cumulative live birth rates across multiple cycles further increase with each additional transfer of vitrified embryos.

Safety data for IVF is well-established. Ovarian hyperstimulation syndrome (OHSS) — the primary serious complication of stimulation — has been dramatically reduced in incidence by GnRH antagonist protocols and agonist triggers, occurring in severe form in fewer than 1–2% of cycles at modern clinics. Perinatal outcomes for IVF-conceived singletons are largely comparable to naturally conceived pregnancies when confounders are controlled, with slightly elevated rates of preterm birth and low birth weight attributable primarily to multiple gestation rather than IVF itself — reinforcing the global shift toward single embryo transfer.